TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Nvidia's Gaming Transition Spells an Opportunity for Patient Investors
JIM CRAMER

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

PRESS RELEASES

Ligand Announces Clinical And Regulatory Progress By Multiple Partners With OmniAb® Antibodies

PRESS RELEASES

Ligand's Captisol Technology Plays Key Role In The Manufacture Of Gilead's Veklury, The First FDA-Approved COVID-19 Treatment

PRESS RELEASES

Ligand Provides Highlights From Today's Investor Day Event

PRESS RELEASES

Ligand To Divest Vernalis Research Operations

PRESS RELEASES

Ligand To Host Virtual Investor Day On October 20th

PRESS RELEASES

Ligand Announces Expiration Of Tender Offer For Shares Of Pfenex Inc.

PRESS RELEASES

Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions Of XCella Biosciences And Taurus Biosciences

PRESS RELEASES

Ligand Pharmaceuticals Management To Present At The H.C. Wainwright 22nd Annual Global Investment Virtual Conference

PRESS RELEASES

Ligand Commences Previously Announced Cash Tender Offer To Acquire Pfenex Inc.

PRESS RELEASES

Ligand OmniAb® Partner Immunovant Announced Positive Topline Results From Multicenter, Placebo-Controlled Phase 2a Trial Of IMVT-1401 In Myasthenia Gravis

PRESS RELEASES

Ligand Announces Amgen's KYPROLIS® Approved By FDA As Combination Regimen With DARZALEX® And Dexamethasone In Once- And Twice-Weekly Dosing Regimens For Patients With Relapsed/Refractory Multiple Myeloma

PRESS RELEASES

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

PRESS RELEASES

PFENEX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale Of PFNX And Encourages Investors To Contact The Firm

PRESS RELEASES

Ligand To Acquire Pfenex Inc.

PRESS RELEASES

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B Cell Select™ And Single Step Cloning Hybridoma Technologies

PRESS RELEASES

IPA Confirms Discovery Of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

PRESS RELEASES

Ligand Announces An Expansion Of Vernalis Collaboration With Servier For Research On Novel Oncology Targets

PRESS RELEASES

Ligand CEO Issues Letter To Captisol Customers

PRESS RELEASES

Ligand Announces Icagen's Expansion Of Collaboration With Roche To Develop And Commercialize Therapies For Neurological Diseases

PRESS RELEASES

Ligand Earns $3 Million Milestone Payment From Palvella Therapeutics

PRESS RELEASES

ImmunoPrecise Provides Updates On B Cell Select™ And Deep Display™ Programs For SARS-CoV-2 Antibody Discovery

PRESS RELEASES

Ligand Provides A Corporate Update And Announces May 6th As The Date For First Quarter Earnings Call

PRESS RELEASES

Ligand Completes Acquisition Of Icagen Core Assets, Partnered Programs And Ion Channel Technologies

PRESS RELEASES

Ligand's Presentation At The Barclays Global Healthcare Conference Now A Webcast Only, New Slides Available On Ligand.com